Reaffirmed: The Medicines (NASDAQ:MDCO) Neutral Rating Reaffirmed at Citigroup; $43 Target in Place

July 17, 2017 - By Clifton Ray

 Reaffirmed: The Medicines (NASDAQ:MDCO) Neutral Rating Reaffirmed at Citigroup; $43 Target in Place

Investors sentiment decreased to 1.12 in 2016 Q4. Its down 0.04, from 1.16 in 2016Q3. It worsened, as 33 investors sold The Medicines Company shares while 53 reduced holdings. 25 funds opened positions while 71 raised stakes. 80.06 million shares or 1.63% less from 81.39 million shares in 2016Q3 were reported.

Blackrock Invest Mgmt Ltd Liability has 0.01% invested in The Medicines Company (NASDAQ:MDCO). Bnp Paribas Arbitrage Sa reported 12,718 shares stake. Sg Americas Secs Ltd Liability holds 0.02% or 68,205 shares. 15,764 are held by Employees Retirement Association Of Colorado. Signpost Capital Advsr Ltd Partnership reported 110,883 shares. Partner Inv Ltd Partnership holds 2.77% in The Medicines Company (NASDAQ:MDCO) or 61,554 shares. Hsbc Hldgs Public Ltd holds 26,749 shares. Kbc Gp Nv accumulated 86,538 shares or 0.03% of the stock. Voya Investment Mgmt Limited Liability holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 28,063 shares. Broadfin Capital Ltd Liability Co holds 436,400 shares or 1.64% of its portfolio. Blackrock, a New York-based fund reported 7,177 shares. Rhumbline Advisers has invested 0.01% in The Medicines Company (NASDAQ:MDCO). 6,066 were accumulated by Addison Capital. Moreover, National Bank & Trust Of Ny Mellon Corporation has 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 814,790 shares. Legal & General Gp Inc Public Ltd holds 120,906 shares.

Since February 3, 2017, it had 0 buys, and 2 sales for $4.07 million activity. On Friday, February 3 the insider O’Connor William Bernard sold $1.19 million.

The Medicines (NASDAQ:MDCO) Rating Reaffirmed

New York: In a research report made public on Monday, 17 July, Citigroup maintained their Neutral rating on The Medicines (NASDAQ:MDCO) shares. They now have a $43 target price on the firm. Citigroup’s target would indicate a potential upside of 11.92 % from the company’s previous stock close.

Investors sentiment decreased to 1.12 in 2016 Q4. Its down 0.04, from 1.16 in 2016Q3. It worsened, as 33 investors sold The Medicines Company shares while 53 reduced holdings. 25 funds opened positions while 71 raised stakes. 80.06 million shares or 1.63% less from 81.39 million shares in 2016Q3 were reported.

Blackrock Invest Mgmt Ltd Liability has 0.01% invested in The Medicines Company (NASDAQ:MDCO). Bnp Paribas Arbitrage Sa reported 12,718 shares stake. Sg Americas Secs Ltd Liability holds 0.02% or 68,205 shares. 15,764 are held by Employees Retirement Association Of Colorado. Signpost Capital Advsr Ltd Partnership reported 110,883 shares. Partner Inv Ltd Partnership holds 2.77% in The Medicines Company (NASDAQ:MDCO) or 61,554 shares. Hsbc Hldgs Public Ltd holds 26,749 shares. Kbc Gp Nv accumulated 86,538 shares or 0.03% of the stock. Voya Investment Mgmt Limited Liability holds 0% of its portfolio in The Medicines Company (NASDAQ:MDCO) for 28,063 shares. Broadfin Capital Ltd Liability Co holds 436,400 shares or 1.64% of its portfolio. Blackrock, a New York-based fund reported 7,177 shares. Rhumbline Advisers has invested 0.01% in The Medicines Company (NASDAQ:MDCO). 6,066 were accumulated by Addison Capital. Moreover, National Bank & Trust Of Ny Mellon Corporation has 0.01% invested in The Medicines Company (NASDAQ:MDCO) for 814,790 shares. Legal & General Gp Inc Public Ltd holds 120,906 shares.

Since February 3, 2017, it had 0 buys, and 2 sales for $4.07 million activity. On Friday, February 3 the insider O’Connor William Bernard sold $1.19 million.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

Among 7 analysts covering The Medicines Co (NASDAQ:MDCO), 6 have Buy rating, 0 Sell and 1 Hold. Therefore 86% are positive. The Medicines Co has $65 highest and $44 lowest target. $54.38’s average target is 41.54% above currents $38.42 stock price. The Medicines Co had 18 analyst reports since August 28, 2015 according to SRatingsIntel. The firm earned “Buy” rating on Monday, August 31 by Leerink Swann. The firm has “Buy” rating given on Monday, March 21 by Chardan Capital Markets. H.C. Wainwright initiated the shares of MDCO in report on Monday, December 5 with “Buy” rating. The rating was maintained by RBC Capital Markets on Monday, November 16 with “Outperform”. The stock of The Medicines Company (NASDAQ:MDCO) earned “Outperform” rating by RBC Capital Markets on Wednesday, November 16. The rating was maintained by RBC Capital Markets with “Outperform” on Monday, August 31. Oppenheimer maintained The Medicines Company (NASDAQ:MDCO) on Monday, August 31 with “Market Perform” rating. The rating was initiated by Chardan Capital Markets with “Buy” on Wednesday, November 4. The company was maintained on Wednesday, July 12 by Oppenheimer. The stock has “Buy” rating by JP Morgan on Saturday, August 29.

About 500,410 shares traded. The Medicines Company (NASDAQ:MDCO) has risen 16.70% since July 17, 2016 and is uptrending. It has by 0.00% the S&P500.

Investors wait The Medicines Company (NASDAQ:MDCO) to report on July, 26. its quarterly earnings Wall Street analysts expect $-1.24 EPS, down $0.40 or 47.62 % from last year’s $-0.84 same quarter earnings. The Medicines Company’s Wall Street analysts see -13.89 % EPS growth, taking into account the $-1.44 EPS reproted in the previous quarter,

The Medicines Company is a global biopharmaceutical company. The company has market cap of $2.80 billion. The Firm is focused on advancing the treatment of acute and intensive care patients through the delivery of medicines to the hospital marketplace around the world. It currently has negative earnings. It markets Angiomax , Ionsys (fentanyl iontophoretic transdermal system), Minocin (minocycline) for injection and Orbactiv (oritavancin).

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.